上海首支生物制造产业基金启动

Core Insights - The launch of Shanghai's first industry fund focused on biomanufacturing marks a significant development in the sector, driven by the collaboration between Daotong Investment and Aopumai [1][2] - The biomanufacturing industry is experiencing rapid growth globally, with the market size increasing from $5.3 billion in 2018 to over $17 billion in 2023, and projected to reach nearly $50 billion by 2028 [2][3] Group 1 - The newly established fund employs a "C (industry chain leader) + VC (professional investment institution)" dual-drive model to leverage Aopumai's industry advantages and Daotong Investment's expertise in early-stage medical and synthetic biology [1] - The "Value Partner Council" will focus on four collaborative directions: resource and platform sharing, technology and results transformation, application and capital synergy, and talent and ecosystem co-cultivation [2] - The initiative aims to create a sustainable industry infrastructure and foster the development of a high-end biomanufacturing cluster in China [2] Group 2 - The Chinese government emphasizes the importance of biomanufacturing, with plans to establish a growth mechanism for future industries, including biomanufacturing, quantum technology, and 6G [3] - China's biomanufacturing industry is approaching a total scale of 1 trillion yuan, maintaining a competitive edge in the global landscape [3]